Esperion Therapeutics Inc. (ESPR) remains on track to initiate a phase III development program with ETC-1002, an investigational, once-daily LDL-C lowering small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies, by the end of 2015.